Atlas Venture Parallel Fund V-b C V - Net Worth and Insider Trading

Atlas Venture Parallel Fund V-b C V Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Atlas Venture Parallel Fund V-b C V owns 2 companies in total, including Alnylam Pharmaceuticals Inc (ALNY) , and Momenta Pharmaceuticals Inc (MNTA) .

Click here to see the complete history of Atlas Venture Parallel Fund V-b C V’s form 4 insider trades.

Insider Ownership Summary of Atlas Venture Parallel Fund V-b C V

Ticker	Comapny	Transaction Date	Type of Owner
ALNY	Alnylam Pharmaceuticals Inc	2004-05-27	10 percent owner
MNTA	Momenta Pharmaceuticals Inc	2005-08-03	10 percent owner

Atlas Venture Parallel Fund V-b C V Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Atlas Venture Parallel Fund V-b C V Ownership Network

Ownership Network List of Atlas Venture Parallel Fund V-b C V

No Data

Ownership Network Relation of Atlas Venture Parallel Fund V-b C V

Atlas Venture Parallel Fund V-b C V Owned Company Details

What does Alnylam Pharmaceuticals Inc do?

Who are the key executives at Alnylam Pharmaceuticals Inc?

Atlas Venture Parallel Fund V-b C V is the 10 percent owner of Alnylam Pharmaceuticals Inc. Other key executives at Alnylam Pharmaceuticals Inc include EVP & Chief Commercial Officer Yvonne Greenstreet , EVP & Chief Commercial Officer Tolga Tanguler , and CMO & EVP Dev & Med Affairs Pushkal Garg .

Alnylam Pharmaceuticals Inc (ALNY) Insider Trades Summary

Over the past 18 months, Atlas Venture Parallel Fund V-b C V made no insider transaction in Alnylam Pharmaceuticals Inc (ALNY). Other recent insider transactions involving Alnylam Pharmaceuticals Inc (ALNY) include a net sale of 60,146 shares made by Yvonne Greenstreet , a net sale of 14,598 shares made by Pushkal Garg , and a net sale of 6,616 shares made by Jeffrey V. Poulton .

In summary, during the past 3 months, insiders sold 135,278 shares of Alnylam Pharmaceuticals Inc (ALNY) in total and bought 0 shares, with a net sale of 135,278 shares. During the past 18 months, 269,382 shares of Alnylam Pharmaceuticals Inc (ALNY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 269,382 shares.

Alnylam Pharmaceuticals Inc (ALNY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alnylam Pharmaceuticals Inc Insider Transactions

No Available Data

Atlas Venture Parallel Fund V-b C V Mailing Address

Above is the net worth, insider trading, and ownership report for Atlas Venture Parallel Fund V-b C V. Currently GuruFocus does not have mailing address information for Atlas Venture Parallel Fund V-b C V.

Discussions on Atlas Venture Parallel Fund V-b C V

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.